29-
C. Gewinner, Z.C. Wang, A. Richardson,
et al.
Evidence that inositol
polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K
signaling.
Cancer Cell, 16 (2009), pp. 115–125.
30-
C.G. Fedele, L.M. Ooms, M. Ho,
et al.
Inositol polyphosphate 4-phosphatase II
regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Proc Natl
Acad Sci U S A, 107 (2010), pp. 22231–22236.
31-
Schiff, Rachel, Suleiman Massarweh, Jiang Shou, et C Kent Osborne.
2003. Breast cancer endocrine resistance: how growth factor signaling and
estrogen receptor coregulators modulate response.
Clinical Cancer Research: An
Official Journal of the American Association for Cancer Research
9, n°. 1
(Janvier): 447S-54S.
32-
Johnston, Stephen Rd. 2005. Combinations of endocrine and biological
agents: present status of therapeutic and presurgical investigations.
Clinical
Cancer Research: An Official Journal of the American Association for Cancer
Research
11, n°. 2 (Janvier 15): 889s-99s.
33-
Balasenthil, Seetharaman, Christopher J Barnes, Suresh K Rayala, et
Rakesh Kumar. 2004. Estrogen receptor activation at serine 305 is sufficient to
upregulate cyclin D1 in breast cancer cells.
FEBS Letters
567, n°. 2 (Juin 4): 243-
247.
34-
Bunone, G, P A Briand, R J Miksicek, et D Picard. 1996. Activation of the
unliganded estrogen receptor by EGF involves the MAP kinase pathway and
direct phosphorylation.
The EMBO Journal
15, n°. 9 (Mai 1): 2174-2183.
35-
Rayala, Suresh K, Amjad H Talukder, Seetharaman Balasenthil, Robbin
Tharakan, Christopher J Barnes, Rui-An Wang, C Marcelo Aldaz, Sohaib Khan,
et Rakesh Kumar. 2006. P21-activated kinase 1 regulation of estrogen receptor-
alpha activation involves serine 305 activation linked with serine 118
phosphorylation.
Cancer Research
66, n°. 3 (Février 1): 1694-1701.
36-
Zwart, Wilbert, Alexander Griekspoor, Valeria Berno, Kim Lakeman, Kees
Jalink, Michael Mancini, Jacques Neefjes, et Rob Michalides. 2007. PKA-induced
resistance to tamoxifen is associated with an altered orientation of ERalpha
towards co-activator SRC-1.
The EMBO Journal
26, n°. 15 (Août 8) : 3534-3544.
18
